Not exact matches
Further evidence
of the decline can be seen in the
decreasing rates of first - time patents since the 1980s, as well as increases in demand for professional licensing, which could further restrict new business opportunities by
requiring expensive (and often unnecessary) credentials.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount
required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and
decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange
rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
It has created a long - term target
of significantly
decreasing the multiple birth
rate from IVF, and it
requires each clinic to develop an annual plan to meet this goal.
Surprisingly, higher use
of reminders did not
decrease the
rate of events
requiring medical attention.
Together, these observations demonstrate that blood - forming stem cells
require a highly regulated
rate of protein synthesis, such that increases or
decreases in that
rate impair stem cell function.
In the most commonly sold supplement form, BCAAs
require no digestion and are quite rapidly absorbed into the bloodstream — which is really neat because it means BCAAs can be used as an immediate energy source during your training sessions, and they will quickly act to
decreasing the
rate of protein breakdown.
However, the faster update
rate of the electrophoretic display media, which is
required, results in a much higher power requirement than usual as well as a
decrease in the display lifetime.
As a result, a discount
rate that is higher is
required which in turn
decreases the pricing
of the bond.
To the extent currency exchange transactions do not fully protect a Fund against adverse changes in currency exchange
rates,
decreases in the value
of currencies
of the foreign countries in which a Fund will invest relative to the U.S. dollar will result in a corresponding
decrease in the U.S. dollar value
of a Fund's assets denominated in those currencies (and possibly a corresponding increase in the amount
of securities
required to be liquidated to meet distribution requirements).
Healthy animals can combat long periods
of starvation through
decreased metabolic
rate, but animals that are sick or injured
require more energy, which increases metabolism.
The
required supplies (BOX 3) are minimal in cost — $ 0.26 per patient — but offer the ability to further
decrease the use
of inhalant agents and the maintenance fluid
rate, thereby preventing use
of hypotensive treatments and further reducing the clinic's overhead cost.
And even with strong international climate policies, more rapid decarbonization (the
rate of decrease in emissions per unit
of GDP) will
require higher costs and major policy change.
Since you are trying to match the past and the
rate of warming is
decreasing it
requires that your models run cool at earlier times.
Two days earlier EPA announced final regulations (which I call the Skyrocketing
Rates Power Plan or SRPP, but which EPA calls the «Clean Power Plan» or CPP for obvious reasons)
requiring states to
decrease CO2 emissions from electricity production and use primarily by increasing the capacity
of non-hydro «remewable» (wind and solar) sources
of electric power from 4 percent to 28 percent by 2030.
According to analysis from Project Catalyst hitting this goal
requires a 17 gigaton
decrease in annual greenhouse gas emissions to 44 gigatons per year from the projected increase
of global emissions
of 61 gigatons by 2020 if we continue polluting at current
rates (Figure 1).
Budget 2015 proposes to
decrease the
required annual minimum withdrawals so they are more in line with long - term investment returns and expected
rates of inflation.
Few prevention programs have been rigorously evaluated, and only a few have proven effective.60, 61 Health - care based prevention programs, including parent education programs to reduce
rates of abusive head trauma, and improving physician ambulatory care practices to help families
decrease risk factors for child maltreatment have shown good initial results, but
require further evaluation.62, 63 Specific intensive home visitation programs such as nurse home visiting programs for first - time mothers have proven to be both clinically and cost effective in preventing maltreatment.64, 65 However, a program
of nurse home visitation has been found ineffective as a treatment model for abusive and neglectful families, highlighting the importance
of primary prevention, as well as the need to rigorously evaluate potential treatments for abusive families.66 Child welfare services are historically structured as short - term interventions that monitor families for recidivism, provide parenting education and assist with referrals to community - based services.
Once again as your conversion
rates increase, the amount
of leads you will
require to reach your goal will
decrease.